Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Signs Manufacturing Agreement

Globe Newswire July 31, 2013

Acasti Announces First Quarter Results

Globe Newswire July 15, 2013

Neptune Announces Issuance of Shares Under Previously Announced Royalty Prepayment Agreement That Increases Its Equity Participation in Acasti Pharma Inc.

Globe Newswire July 12, 2013

Acasti Reports Results of Annual and Special Meeting

Globe Newswire June 28, 2013

Acasti Announces Fiscal 2013 Results and Provides Update on Status of Clinical Trials

Globe Newswire May 22, 2013

The U.S. International Trade Commission (ITC) Votes to Institute Patent Infringements Investigation Based on Neptune & Acasti Complaint

Globe Newswire April 15, 2013

Acasti Pharma Presents Preliminary Data Moving Forward With Clinical Strategy

Troy Schwensen March 19, 2013

Neptune to Present at the Annual ROTH Conference

Troy Schwensen March 14, 2013

Neptune Responds to Aker BioMarine's Attempt to Shift the Focus From Neptune's Major ITC Filing

Troy Schwensen January 31, 2013

Neptune Files ITC Complaint Against Competitors Aker, Enzymotec, Rimfrost, Olympic and Others

Troy Schwensen January 30, 2013

Neptune Obtains Allowance of Patent Specific to Krill Oil and Announces Management Reorganization

Troy Schwensen January 24, 2013

Acasti Pharma Reports Its Third Quarter Results

Troy Schwensen January 15, 2013

Neptune to Hold Conference Call

Troy Schwensen January 14, 2013

Neptune to Hold Conference Call

Troy Schwensen January 7, 2013

Acasti Pharma Shares to Trade on NASDAQ

Troy Schwensen January 7, 2013

Neptune Files for Revocation of Aker's Australian Patents

Troy Schwensen December 21, 2012